Published in Arch Intern Med on September 09, 1996
Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease. JAMA (2015) 3.89
Thrombolysis for acute ischaemic stroke: consumer involvement in design of new randomised controlled trial. BMJ (2002) 2.87
Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes (2010) 2.17
Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes (2014) 1.65
Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. Eur Heart J (2014) 1.54
Risk of stroke and oral anticoagulant use in atrial fibrillation: a cross-sectional survey. Br J Gen Pract (2012) 1.46
Cost-effectiveness of treating resistant hypertension with an implantable carotid body stimulator. J Clin Hypertens (Greenwich) (2009) 1.41
Cost-effectiveness of latent tuberculosis screening before steroid therapy for idiopathic nephrotic syndrome in children. Am J Kidney Dis (2012) 1.40
Thrombolytic treatment for acute ischaemic stroke: consent can be ethical. BMJ (1998) 1.31
Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence (2010) 1.26
Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents. Am Heart J (2014) 1.26
Understanding patients' preferences for treatment: the need for innovative methodologies. Qual Health Care (2001) 1.18
Novel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation--a cost-effectiveness analysis. J Gen Intern Med (2013) 1.09
A new instrument for measuring anticoagulation-related quality of life: development and preliminary validation. Health Qual Life Outcomes (2004) 1.09
How well do guidelines incorporate evidence on patient preferences? J Gen Intern Med (2009) 1.08
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart (2012) 1.05
Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. PLoS One (2012) 0.99
Cost-effectiveness of a potential vaccine for Coccidioides immitis. Emerg Infect Dis (2001) 0.97
Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation. PLoS One (2012) 0.93
A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation. Eur Heart J (2012) 0.93
Cost-effectiveness of automated external defibrillator deployment in selected public locations. J Gen Intern Med (2003) 0.91
Should we test for CYP2C9 before initiating anticoagulant therapy in patients with atrial fibrillation? J Gen Intern Med (2009) 0.90
Aspirin for secondary prevention after stroke of unknown etiology in resource-limited settings. Neurology (2014) 0.89
Drug adherence in patients taking oral anticoagulation therapy. Clin Res Cardiol (2013) 0.87
Calculating the risk benefit equation for aggressive treatment of non-convulsive status epilepticus. Neurocrit Care (2013) 0.86
The development and preliminary validation of a Preference-Based Stroke Index (PBSI). Health Qual Life Outcomes (2003) 0.83
Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands. PLoS One (2014) 0.82
Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting. Pharmacoeconomics (2013) 0.82
Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation. Clin Pharmacol Ther (2013) 0.80
Carotid artery stenosis: cost-effectiveness of assessment of cerebrovascular reserve to guide treatment of asymptomatic patients. Radiology (2014) 0.79
Developing an Atrial Fibrillation Guideline Support Tool (AFGuST) for shared decision making. Curr Med Res Opin (2015) 0.79
Cost-effectiveness of in-home automated external defibrillators for individuals at increased risk of sudden cardiac death. J Gen Intern Med (2005) 0.78
Cost-Effectiveness of Carotid Plaque MR Imaging as a Stroke Risk Stratification Tool in Asymptomatic Carotid Artery Stenosis. Radiology (2015) 0.78
Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes: A Pooled Analysis of 9 Trials. Stroke (2016) 0.78
Medical decision making and the counting of uncertainty. Circulation (2014) 0.77
Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany. Biomed Res Int (2015) 0.77
Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin. Europace (2016) 0.77
Development and implementation of a decision support system for carotid artery stenosis: the Carotid Ultrasound Report Enhancement (CURE). Proc AMIA Symp (2000) 0.76
Weighing the value of memory loss in the surgical evaluation of left temporal lobe epilepsy: a decision analysis. Epilepsia (2014) 0.76
Comparative analysis of cervical spine management in a subset of severe traumatic brain injury cases using computer simulation. PLoS One (2011) 0.76
Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation. BMC Cardiovasc Disord (2016) 0.75
Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences. BMC Health Serv Res (2017) 0.75
Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden. Pharmacogenomics J (2016) 0.75
Health state descriptions to elicit stroke values: do they reflect patient experience of stroke? BMC Health Serv Res (2014) 0.75
Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses. PLoS One (2016) 0.75
Genetic risk for atrial fibrillation could motivate patient adherence to warfarin therapy: a cost effectiveness analysis. BMC Cardiovasc Disord (2015) 0.75
Minimizing bleeding risk in patients receiving direct oral anticoagulants for stroke prevention. Int J Gen Med (2016) 0.75
Quantifying the utility of taking pills for preventing adverse health outcomes: a cross-sectional survey. BMJ Open (2015) 0.75
Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL. Circ Arrhythm Electrophysiol (2016) 0.75
Decision analysis of intracranial monitoring in non-lesional epilepsy. Seizure (2016) 0.75
Modeling the Cost Effectiveness of Neuroimaging-Based Treatment of Acute Wake-Up Stroke. PLoS One (2016) 0.75
Modeling stroke management: a qualitative review of cost-effectiveness analyses. Eur J Health Econ (2010) 0.75
Validation of a Cardiovascular Disease Policy Microsimulation Model Using Both Survival and Receiver Operating Characteristic Curves. Med Decis Making (2017) 0.75
Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA (2001) 5.10
Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet (1996) 5.03
Electronic trial banks: a complementary method for reporting randomized trials. Med Decis Making (2001) 3.83
Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA (1995) 3.21
The role of coronary angiography and coronary revascularization before noncardiac vascular surgery. JAMA (1995) 2.38
Echocardiography in patients with suspected endocarditis: a cost-effectiveness analysis. Am J Med (1999) 2.13
Interpretation of cost-effectiveness analyses. J Gen Intern Med (1998) 1.85
A randomized controlled trial of a computer-based physician workstation in an outpatient setting: implementation barriers to outcome evaluation. J Am Med Inform Assoc (1997) 1.83
Validation of two models to estimate the probability of malignancy in patients with solitary pulmonary nodules. Thorax (2007) 1.68
Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis. Ann Intern Med (1997) 1.66
Bioterrorism preparedness and response: use of information technologies and decision support systems. Evid Rep Technol Assess (Summ) (2002) 1.61
Employment and alcohol use after liver transplantation for alcoholic and nonalcoholic liver disease: a systematic review. Liver Transpl (2001) 1.55
Projected long-term costs of coronary stenting in multivessel coronary disease based on the experience of the Bypass Angioplasty Revascularization Investigation (BARI). Am Heart J (2000) 1.38
A computer-based interview to identify HIV risk behaviors and to assess patient preferences for HIV-related health states. Proc Annu Symp Comput Appl Med Care (1994) 1.30
Publishing web-based guidelines using interactive decision models. J Eval Clin Pract (2001) 1.24
Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke (1998) 1.20
Impact of a clinical preventive medicine curriculum for primary care faculty: results of a dissemination model. Prev Med (1992) 1.18
Screening women of childbearing age for human immunodeficiency virus. A cost-benefit analysis. Arch Intern Med (1992) 1.13
Distributed decision support using a web-based interface: prevention of sudden cardiac death. Med Decis Making (1999) 1.12
Health-related quality of life after liver transplantation: a meta-analysis. Liver Transpl Surg (1999) 1.08
A method for estimating the cost-effectiveness of incorporating patient preferences into practice guidelines. Med Decis Making (1995) 1.00
Cost-effectiveness of a potential vaccine for Coccidioides immitis. Emerg Infect Dis (2001) 0.97
Cost-effectiveness of radiofrequency ablation for supraventricular tachycardia. Ann Intern Med (2000) 0.94
A randomized trial of computer-based reminders and audit and feedback to improve HIV screening in a primary care setting. Int J STD AIDS (2009) 0.93
Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther (2004) 0.93
Design and pilot evaluation of a system to develop computer-based site-specific practice guidelines from decision models. Med Decis Making (2000) 0.91
Physicians' assessments of the utility of health states associated with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. Qual Life Res (1997) 0.90
Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Ann Intern Med (2001) 0.90
Helicobacter pylori and gastric cancer: what are the benefits of screening only for the CagA phenotype of H. pylori? Helicobacter (1999) 0.88
Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps. Clin Infect Dis (2000) 0.86
Effect and outcomes of the ASGE guidelines on the periendoscopic management of patients who take anticoagulants. Am J Gastroenterol (2000) 0.84
Quantifying the population impact of a prophylactic Helicobacter pylori vaccine. Vaccine (2001) 0.84
Use of influence diagrams to structure medical decisions. Med Decis Making (1997) 0.84
An analysis of optimal resource allocation for prevention of infection with human immunodeficiency virus (HIV) in injection drug users and non-users. Med Decis Making (1999) 0.84
Regionalization of bioterrorism preparedness and response. Evid Rep Technol Assess (Summ) (2004) 0.83
The cost effectiveness of voluntary prenatal and routine newborn HIV screening in the United States. J Acquir Immune Defic Syndr (2000) 0.83
Helicobacter pylori vaccine development and use: a cost-effectiveness analysis using the Institute of Medicine Methodology. Helicobacter (1999) 0.82
Cost-effectiveness of voluntary HIV screening in Russia. Int J STD AIDS (2009) 0.81
Evaluation of genetic tests: APOE genotyping for the diagnosis of Alzheimer disease. Genet Test (1999) 0.78
Should we treat H. pylori infection to prevent gastric cancer? Gastroenterology (1997) 0.78
A dynamic transmission model for predicting trends in Helicobacter pylori and associated diseases in the United States. Emerg Infect Dis (2000) 0.78
Prevention of sudden cardiac death: a probabilistic model for decision support. Proc Annu Symp Comput Appl Med Care (1995) 0.77
Presentation and explanation of medical decision models using the World Wide Web. Proc AMIA Annu Fall Symp (1996) 0.76
Threshold analysis using diagnostic tests with multiple results. Med Decis Making (1989) 0.76
A randomized evaluation of a computer-based physician's workstation: design considerations and baseline results. Proc Annu Symp Comput Appl Med Care (1995) 0.76
Design of a modular, extensible decision support system for arrhythmia therapy. Proc AMIA Symp (1998) 0.75
Assessment and representation of prior beliefs: unexpected implications of the uniform distribution. Med Decis Making (1990) 0.75
Computer-based decision support: wishing on a star? Eff Clin Pract (2001) 0.75
Cost-effectiveness of tests to assess the risk of sudden death after acute myocardial infarction. J Am Coll Cardiol (1998) 0.75
In the eye of the beholder: assessment of health-related quality of life. Hepatology (1998) 0.75
Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans. J Viral Hepat (2014) 0.75
The release of endogenous amino acids into the vitreous of the intact eye of the albino rat: effect of light, potassium, and ouabain. Brain Res (1981) 0.75
Decision analysis for chest clinicians. Am Rev Respir Dis (1988) 0.75